Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
ln Vitro |
In vitro, krynuramine dihydrobromide inhibits alpha-adrenergic receptors both postsynaptic and presynaptic [2]. It has been demonstrated that kynuramine dihydrobromide partially agonistically interacts with serotonin receptors in canine cerebral arteries [2]. The ileum contracted slightly when exposed to 20 μg/mL of kynuramine dihydrobromide, but this did not change the twitching response to cholinergic stimulation [2].
|
---|---|
ln Vivo |
Kynuramine dihydrobromide (0.064-8 μg; intracerebroventricular; single dosage) increases estrogen-stimulated lordotic behavior in ovariectomized rats[3]. Kynuramine dihydrobromide (1.25-5.0 mg/kg; IV; single dosage) raises heart rate and blood pressure in rats[4].
|
Animal Protocol |
Animal/Disease Models: Female rats[3].
Doses: 0.064, 0.32, 1.6 or 8 μg. Route of Administration: Intraventricular injection; single does. Experimental Results: Produced facilitation of lordosis behavior. Animal/Disease Models: Male rats (about 200g)[4]. Doses: 1.25, 2.5 and 5.0 mg/kg. Route of Administration: intravenous (iv) injection; single does. Experimental Results: Promoted heart rate and blood pressure. |
References |
[1]. J B Massey, et al. Kynuramine, a fluorescent substrate and probe of plasma amine oxidase. J Biol Chem. 1977 Nov 25;252(22):8081-4.
[2]. T D Johnson, An alpha-adrenoceptor inhibitory action of kynuramine. Eur J Pharmacol. 1981 Jul 10;72(4):351-6. [3]. S D Mendelson, et al. Intraventricular administration of l-kynurenine and kynuramine facilitates lordosis in the female rat. Eur J Pharmacol. 1987 Oct 27;142(3):447-51. [4]. T D Johnson, et al. Blood pressure and heart rate effects of kynuramine in pithed rats. Eur J Pharmacol. 1983 Feb 18;87(2-3):323-6. |
Molecular Formula |
C9H14BR2N2O
|
---|---|
Molecular Weight |
326.03
|
CAS # |
304-47-2
|
Related CAS # |
Kynuramine dihydrochloride;36681-58-0
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
Br.NCCC(C1=CC=CC=C1N)=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0672 mL | 15.3360 mL | 30.6720 mL | |
5 mM | 0.6134 mL | 3.0672 mL | 6.1344 mL | |
10 mM | 0.3067 mL | 1.5336 mL | 3.0672 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.